Clear Street’s Alpha Tau Medical DRTS Stock Holding History

Clear Street’s Portfolio DRTS Stock Details DRTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,500	Closed	-$30K	–	1033
2022 Q1	$30K	Buy	+2,500	New	+$29.4K	﹤0.01%	170

Other funds holding DRTS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Clear Street's DRTS Position: Q2 2022 in Review

Clear Street sold out of Alpha Tau Medical (DRTS) in Q2 2022, closing a stake of 2,500 shares — an estimated $30K sold.

Clear Street first reported a position in DRTS in Q1 2022 and held it in 1 quarter. The position peaked at $30K in Q1 2022. 14 funds tracked by Wall St. Rank hold DRTS as of Q2 2022.

Clear Street reported no remaining Alpha Tau Medical position as of Q2 2022 after selling out during the quarter.
Clear Street sold 2,500 Alpha Tau Medical shares in Q2 2022, an estimated $30K.
Clear Street first reported a position in Alpha Tau Medical in Q1 2022 and held it in 1 quarter.
Clear Street's Alpha Tau Medical position peaked at $30K in Q1 2022.
14 funds tracked by Wall St. Rank held Alpha Tau Medical as of Q2 2022.

Based on Clear Street's 13F filing for Q2 2022, filed 2 Aug 2022.